Protocol Ledger

Therapeutic Cohort RSP · ClinicalTrials.gov API v2

Respiratory and Pulmonary: Phase II & III Clinical Trial Benchmarks

Protocol Ledger tracks 1,201 interventional Phase II and Phase III Respiratory and Pulmonary protocols registered from 2018 through 2026, including 435 active studies, 506 completed studies, and 146 early-stopped studies (12.16% overall; 22.39% of closed trials).

Median Enrollment: 91.0 participants Median Completed Span: 651 days California Share: 320 studies (26.6%)

1. Reconciled Respiratory and Pulmonary Execution & Stop-Cause Profile

Respiratory and Pulmonary Cohort Metrics (Publication 47c4426df7e9d67d5bfe)
Clinical Trial Metric Verified Value Operational Context
Total Phase II & III Protocols (2018 to 2026) 1,201 Deterministic primary MeSH and condition-keyword assignment
Active Concurrent Pipeline 435 Recruiting, enrolling by invitation, and active follow-up protocols
Completed vs Prematurely Stopped 506 / 146 22.39% closed-trial attrition ratio across 652 closed protocols
Slow Accrual vs Safety & Futility Stops 22 / 26 / 12 Slow accrual (WS1) vs clinical safety (WS4) vs interim futility (WS5)
Physical Hospital Site Disclosure Rate 56.6% Named hospital campus participations vs anonymized CRO site slots

2. Leading Consolidated Trial Sponsors Focused on Respiratory and Pulmonary

Consolidated Biopharma, Academic & Federal Sponsors (Respiratory and Pulmonary Primary Focus)
Sponsor Hub Sector Protocols Active Completed FDA NDA/BLA
Vertex Pharmaceuticals Biopharma Industry 78 26 48 10
Chiesi Farmaceutici S.p.A Biopharma Industry 33 10 13 0
Eurofarma Laboratorios Biopharma Industry 22 2 8 0
Genrix (Shanghai) Biopharmaceutical Co Biopharma Industry 21 10 6 0

3. Representative Multi-Center Phase II & III Respiratory and Pulmonary Studies

Indexed ClinicalTrials.gov v2 Study Dossiers in Respiratory and Pulmonary
NCT Study Protocol Brief Title Sponsor Phase Status
NCT07208591 To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome Staidson (Beijing) Biopharmaceuticals Co Phase III RECRUITING
NCT04965298 Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole Norfolk and Norwich University Hospitals NHS Foundation Trust Phase III RECRUITING
NCT06829784 TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co Phase III RECRUITING
NCT06347536 Supported Rescue Packs Post-discharge in Chronic Obstructive Pulmonary Disease Guy's and St Thomas' NHS Foundation Trust Phase III RECRUITING
NCT07121413 A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis Shanghai Synvida Biotechnology Co Phase II RECRUITING
NCT07687459 Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) InSilico Medicine Hong Kong Limited Phase III RECRUITING
NCT07402551 Phase II Study of RC1416 Injection in COPD Nanjing RegeneCore Biotech Co Phase II RECRUITING
NCT07398859 Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co Phase II RECRUITING
NCT07464587 Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease Chia Tai Tianqing Pharmaceutical Group Co Phase III RECRUITING
NCT07292714 A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Mabwell (Shanghai) Bioscience Co Phase II RECRUITING
NCT07516951 A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis Chiesi Farmaceutici S.p.A Phase II RECRUITING
NCT07403487 Phase II Trial of RC1416 Injection in Asthma Nanjing RegeneCore Biotech Co Phase II RECRUITING
NCT05008965 Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma Oneness Biotech Co Phase II RECRUITING
NCT06703073 JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record) PPD Development, LP Phase II RECRUITING
NCT06701682 JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab PPD Development, LP Phase II RECRUITING
NCT06701669 JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart PPD Development, LP Phase II RECRUITING

Related Therapeutic Condition Hubs & Crosswalks

Compare adjacent clinical cohorts: Oncology and Hematology · Rare Genetic, Women's Health, and Other · Infectious Disease and Vaccines · Neurology, Psychiatry, and Pain, browse the interactive Hospital & Sponsor Directory, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI